At a glance
- Originator GlaxoSmithKline
- Class Antineoplastics
- Mechanism of Action DNA-directed DNA polymerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 18 May 1995 Discontinued-I for Cancer in USA (Unknown route)
- 18 May 1995 Discontinued-I for Cancer in United Kingdom (Unknown route)